See Asa at Microbiome & Probiotic R&D & Business Collaboration Forum - La Jolla, California 10/13/2025
September 10, 2025 By: Asa Waldstein

Ingredient Descriptions Are Claims

Takeaway -

All marketing must be compliant

This warning letter is a great teaching lesson of what not to do. Here are some extreme examples where the company crossed the compliance line by discussing the benefits of its ingredients.

From warning letter:

  • “Not only can elderberry help prevent colds and flu, but it can also be used to treat allergies, including hay fever, and sinus infections.”
  • “Ashwagandha powder can help reduce inflammation.”
  • “The benefits of this adaptogen also extend to fighting inflammation.”
  • “Lion’s Mane mushrooms are thought to protect from dementia.”

Asa comments: Softening words like “may help with” or “are thought to” do not allow the company to make disease claims.

FDA inspected the company’s facility, but according to the warning letter, FDA did not review the company’s website until two months after the inspection. FDA then reviewed the company’s website again three months later. Here are some takeaways.

If you have been inspected by FDA within the past year, now is the time to triple-check your online presence to ensure there are no “forgotten” disease statements.

You can correct your online presence now, and if FDA is surveilling your website and sees that the disease claims have been removed, this reduces your warning letter risk. It’s “almost” never too late to be compliant.

Here’s the letter.

Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading.

Written by

Asa Waldstein
Asa Waldstein
Asa Waldstein is a 24-year veteran of the dietary supplement industry, with experience spanning manufacturing, marketing, and regulatory compliance. He is the principal of Apex Compliance, a software company dedicated to streamlining regulatory marketing compliance for the dietary supplement and natural products sectors. Asa also leads Supplement Advisory Group, a boutique consultancy focused on marketing risk analysis, labeling, and practical compliance strategies for websites and social media. Asa has helped oversee three FDA GMP inspections with no 483s and was honored with the 2023 AHPA Herbal Hero Award and the 2024 What's Up Supps Policy and Change Agent Award. He currently serves as Chair of the American Herbal Products Association’s (AHPA) Cannabis Committee, helping shape policy and industry best practices